Tags Archive Navigation
icon
-
Media ReleaseAlcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
-
Media ReleaseNovartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
-
Media ReleaseNovartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittliche Therapieplattformen voran, um das zukünftige Wachstum zu beschleunigen
-
Media ReleaseNovartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
-
Media ReleaseNovartis a enregistré, au troisième trimestre, une forte croissance et fait preuve d'une innovation dynamique, incluant des plateformes thérapeutiques avancées pour soutenir la croissance future
-
Media ReleaseNovartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
-
Media ReleaseAlcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
-
Media ReleaseNovartis announces new CEO of Oncology Business Unit
-
Media ReleaseNovartis successfully completes acquisition of Endocyte
-
Media ReleaseNovartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das Unternehmen
-
Media ReleaseEn 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entreprise
-
Media ReleaseNovartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
Pagination
- ‹ Previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- › Next page